SecBot SecBot
425 ·Filed Nov 9, 2026

PULM

Pulmatrix, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed7d 19h ago SEC0001493152-26-050616
Rule 425 M&A communications
Actionable Insight • Neutral

Monitor for the December 2026 conference presentation and any updates on Nasdaq listing approval, which is the remaining condition for merger close.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.36
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.84%
T+5 · $1.33
Vs SPY
−0.15%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $1.36entry
  2. T+1 · 7d ago −0.37%α −0.00% · $1.35
  3. T+5 · 20h ago −1.84%α −0.15% · $1.33
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Eos SENOLYTIX announced new preclinical data for PTC-2105 showing it reduced semaglutide-associated lean-mass loss in aged mice, with the presentation upgraded to a plenary slot at an upcoming conference. The filing also confirms the merger with Pulmatrix remains on track for Q4 2026 close, subject to Nasdaq listing approval, after stockholder approval was obtained on October 26, 2026. The data is preclinical and promotional, with no changes to deal terms or financials.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Eos SENOLYTIX will present new preclinical data for PTC-2105 at the 19th Sarcopenia, Cachexia & Wasting Disorders International Conference in December 2026.
  • The presentation was upgraded from a poster to a plenary presentation.
  • PTC-2105 monotherapy reversed terminal lean-mass decline in aged high-fat-fed mice (+0.005 g/wk vs -0.002 g/wk for saline).
  • Co-administration of PTC-2105 with semaglutide reduced late-life lean-mass loss relative to semaglutide alone (+0.126 and -0.011 g/wk vs -0.055 g/wk).
  • Pulmatrix stockholders approved the proposed merger on October 26, 2026.
  • The merger is anticipated to close in Q4 2026, subject to Nasdaq listing approval and customary closing conditions.
  • Combined company common stock expected to trade on Nasdaq under ticker symbol MTXL.
  • All data are from preclinical studies in mice; results may not translate to humans.

Financial Impact

No financial figures disclosed; preclinical data only.

Risk Factors

  • Preclinical data may not translate to human clinical outcomes.
  • Merger closing remains subject to Nasdaq listing approval, which could be delayed or denied.
  • PTC-2105 is an investigational compound not yet approved by any regulatory authority.
  • document contains text addressed to automated readers

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001493152-26-050616
Document: 0001493152-26-050616-index-headers.html0001493152-26-050616
Document: 0001493152-26-050616-index.html0001493152-26-050616
Document: 0001493152-26-050616.txt0001493152-26-050616

Track record

21 reports on PULM

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Nov 9, 20267d ago 425 Neutral 3/10 Viewing Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
  2. Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
  3. Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
  4. Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
  5. Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
  6. Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
  7. Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
  8. Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  9. Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
  10. Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026